Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

News Bristol-Myers Squibb Company Lima

Equities

BMY

US1101221083

End-of-day quote Lima
Other stock markets
 06:00:00 2024-06-30 pm EDT 		5-day change 1st Jan Change
41.18 USD 0.00% Intraday chart for Bristol-Myers Squibb Company 0.00% -19.81%
Jul. 02 Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors CI
Jul. 01 Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Ex-dividend day
FA
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors
CI
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says
MT
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America
AQ
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise
MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours
MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment
MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
MT
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
AQ
Bristol Myers: accelerated approval in colorectal cancer
CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BU
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer
CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval
MT
US FDA approves Bristol Myers' colorectal cancer therapy
RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo
MT
Bristol Myers: application validated for subcutaneous Opdivo
CF
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
BU
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BMY Stock
  5. News Bristol-Myers Squibb Company